top of page

Brooks Hill Partners Invests in Totient

Brooks Hill Partners has announced an investment in Totient, a Boston-based startup that uses advanced immunoinformatics, ML and AI, and immunological research into tertiary lymphoid structures to select and assemble monoclonal antibodies expressed in tissues affected by autoimmunity, infections, and cancer.



UPDATE: Totient was acquired by Absci in Jun. 2021

Interested in learning more?

bottom of page